メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
菊池 潤
内科学(リウマチ・膠原病)
ウェブサイト
https://k-ris.keio.ac.jp/html/100003386_ja.html
h-index
834
被引用数
15
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2010
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(69)
類似のプロファイル
(6)
フィンガープリント
Jun Kikuchiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Systemic Lupus Erythematosus
100%
Disease Activity
74%
Lupus Erythematosus
65%
Cohort Analysis
53%
Interstitial Lung Disease
52%
Rheumatoid Arthritis
31%
Glucocorticoid
30%
Myositis
25%
Polymyositis
24%
Prednisolone
23%
Tocilizumab
23%
Disease
22%
Connective Tissue Disease
21%
Immunoglobulin G4
21%
Chronic Kidney Disease
21%
Large-Cell Lymphoma
21%
Cohort Study
21%
Immunosuppressive Treatment
21%
SLEDAI
19%
Disease Exacerbation
18%
Odds Ratio
17%
Monotherapy
16%
Prevalence
14%
Methotrexate
14%
Combination Therapy
13%
Drug Therapy
13%
Biological Product
13%
Biological Marker
12%
Mental Capacity
12%
Immunosuppressant
12%
Neoplasm
12%
Tacrolimus
11%
Arm
10%
Disease Modifying Antirheumatic Drug
10%
Proton-Pump Inhibitor
10%
Surfactant Protein D
10%
Polyarteritis nodosa
10%
Corticosteroid Therapy
10%
Peripheral Vasodilating Agent
10%
Hypomagnesemia
10%
Malignant Neoplasm
10%
Lupus Nephritis
10%
Plasma Cell
10%
Eotaxin 3
10%
Chylothorax
10%
Lymphocytopenia
10%
Angiography
10%
Recurrent Infection
10%
Laboratory Test
10%
Sarcopenia
10%
Immunology and Microbiology
Systemic Lupus Erythematosus
88%
Inflammatory Arthritis
52%
Glucocorticoid
32%
Lupus Erythematosus
31%
Tocilizumab
24%
Myositis
23%
Disease-Modifying Antirheumatic Drug
21%
Regulatory T Cell
21%
interferon
19%
Abatacept
18%
T Helper Cell
15%
Cytokine
14%
B Cell
14%
Prevalence
13%
Polymyositis
13%
Drug Megadose
13%
C-Reactive Protein
13%
Autoantibodies
12%
Immunosuppressive Therapy
12%
Interleukin 6
12%
Rituximab
11%
Surfactant Protein D
10%
Vaccination Policy
10%
Protein Expression
10%
Severe Acute Respiratory Syndrome Coronavirus 2
10%
Factor VIII
10%
Heavy Chain Disease
10%
Immunoglobulin A
10%
T Cell
10%
Lymphadenopathy
10%
Immunoglobulin G4 Related Disease
10%
Lymphocytopenia
10%
Biological Product
10%
Interferon
10%
Epidermal Growth Factor
10%
Monocyte
10%
Eotaxin 3
10%
Cyclophosphamide
10%
Giant Cell Arteritis
10%
Sarilumab
10%
Centromere Antibody
10%
Anti-Centromere Antibodies
10%
Antimalarial Agent
9%
Infliximab
8%
Bone Mass
8%
Body Weight
6%
Neutrophil Count
5%
Lymphoproliferative Disorders
5%
Vasculitis
5%
Oxygen Saturation
5%
Keyphrases
Rheumatoid Arthritis
57%
Tocilizumab
34%
Intravascular Large B-cell Lymphoma (IVLBCL)
21%
Interstitial Lung Disease
21%
Chronic Kidney Disease
21%
Rheumatic musculoskeletal Disease
21%
Abatacept
17%
Interleukin-6
14%
Tacrolimus
13%
Rheumatoid Arthritis Patients
12%
Poor Prognosis
12%
Japan
11%
Intravenous Cyclophosphamide
10%
Anti-double Stranded DNA
10%
Repeated Testing
10%
Target Prevalence
10%
Clinical Effect
10%
Large Blood Vessels
10%
Multicenter Cohort Study
10%
Cutaneous Arteritis
10%
Poor Survival
10%
Gastrointestinal Bleeding
10%
Systemic Lupus Erythematous
10%
Purpura
10%
Cancer-associated Myositis
10%
Connective Tissue Disease
10%
Polyarteritis Nodosa
10%
Giant Cell Arteritis
10%
Bone Metabolism Markers
10%
IgA Nephropathy (IgAN)
10%
Neuropsychiatric Involvement
10%
Cerebral Infarction
10%
Interleukin-6 Signaling
10%
Lymphadenopathy
10%
Biological Disease-modifying Antirheumatic Drugs (bDMARDs)
10%
Free Treatment
10%
Remission
10%
Renal Disease
10%
Hydroxychloroquine
10%
Recurrent Infection
10%
Immunological Effects
10%
Catheter Angiography
10%
Proton Pump Inhibitors
10%
Multicenter Cohort
10%
New Biomarkers
10%
Autopsy Cases
10%
Peutz
10%
IgG4-related Disease (IgG4-RD)
10%
Seropositive Rheumatoid Arthritis
10%
Hypomagnesemia
10%
